Phase 2 Epilepsy Trial, Recruiting (NCT06483061)

Phase 2 Epilepsy Trial, Recruiting NCT06483061 Sponsor: University of Alberta Condition: Epilepsy

Printed from Voxsanity (voxsanity.com.au) — NCT06483061 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Epilepsy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are a healthy person aged 18 to 64 with no known health conditions
You are aged 18 to 64 and have been diagnosed with temporal lobe epilepsy, with scarring in a part of the brain called the hippocampus that has been seen on an MRI scan

Who may not be able to join:

You do not speak English, as the trial team is unable to provide translation services
You are unable to give your own consent to take part in the study
You have a reason why you cannot safely have an MRI scan (confirm with trial site)
You are under 17 or over 65 years old
You weigh more than 127.5kg (approximately 281 lbs or 20 stone)
You are a woman who could become pregnant and have tested positive on a pregnancy test
You are currently breastfeeding
You have a known allergy or sensitivity to Ferumoxytol (also called Feraheme) or any of its ingredients
You have previously had an allergic reaction to any iron product given through a drip or injection into a vein

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Donald Gross, MD, University of Alberta

Phone: 7809109585

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06483061

Sponsor: University of Alberta

Phase: Phase 2

Status: Recruiting

Condition: Epilepsy

Trial contact: 7809109585

More information: https://clinicaltrials.gov/study/NCT06483061

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are a healthy person aged 18 to 64 with no known health conditions
You are aged 18 to 64 and have been diagnosed with temporal lobe epilepsy, with scarring in a part of the brain called the hippocampus that has been seen on an MRI scan

Who may not be able to join:

You do not speak English, as the trial team is unable to provide translation services
You are unable to give your own consent to take part in the study
You have a reason why you cannot safely have an MRI scan (confirm with trial site)
You are under 17 or over 65 years old
You weigh more than 127.5kg (approximately 281 lbs or 20 stone)
You are a woman who could become pregnant and have tested positive on a pregnancy test
You are currently breastfeeding
You have a known allergy or sensitivity to Ferumoxytol (also called Feraheme) or any of its ingredients
You have previously had an allergic reaction to any iron product given through a drip or injection into a vein

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

University of Alberta

Registry

ClinicalTrials.gov

Start date

1 May 2025

Est. completion

1 September 2029

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Ferumoxytol enhanced cerebral vasculature imaging; Ferumoxytol enhanced cerebral vasculature imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov